Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases
Authors:
- 24 August 2017
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 15 (1) , 33-44
Abstract
Evidence for the increased risk of cardiovascular morbidity and mortality in patients with chronic inflammatory and systemic autoimmune diseases has accumulated during the past 15 years. In these patients, an interplay between several mechanisms, including premature acceleration of subclinical atherosclerotic damage, inflammation, and dysregulation of the immune system, is involved in the induction and progression of atherosclerosis. Moreover, traditional cardiovascular risk factors are also likely to contribute, at least in part, to the excess cardiovascular risk. Among traditional cardiovascular risk factors, hypertension is an important predictor of cardiovascular events in the general population and in patients with chronic inflammatory and autoimmune diseases. Evidence supports the idea that the pathogenic mechanisms underlying the increased blood pressure in these diseases are multifactorial and not only related to the mechanical injury of the arterial wall. In particular, chronic inflammation and immune-mediated mechanisms have been demonstrated to affect blood-pressure control in patients with systemic autoimmune disease. In this Review, we discuss the available evidence on the relationship between hypertension and autoimmune diseases, and describe the multiple factors that might affect blood-pressure control in patients with chronic inflammatory and systemic autoimmune diseases. We also discuss the effect of hypertension and antirheumatic therapies on cardiovascular outcome.Keywords
This publication has 102 references indexed in Scilit:
- Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patientsJournal of Human Hypertension, 2013
- Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective studyArthritis Research & Therapy, 2011
- Tumor Necrosis Factor-α Antagonist Etanercept Decreases Blood Pressure and Protects the Kidney in a Mouse Model of Systemic Lupus ErythematosusHypertension, 2010
- Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coinArthritis Care & Research, 2010
- The Editor's Roundtable: Effect of Nonsteroidal Anti-Inflammatory Drugs on Blood PressureThe American Journal of Cardiology, 2010
- Leptin and Cardiovascular DiseaseCirculation, 2008
- Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid ArthritisCirculation, 2008
- Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA studyArthritis Research & Therapy, 2008
- Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, studyAnnals of the Rheumatic Diseases, 2007
- Arterial Stiffness in Chronic Inflammatory DiseasesHypertension, 2005